Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors
Recruiting
Phase 4
Interventional Study
Pituitary Adenoma
Pituitary Neuroendocrine Tumor
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 70
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 882 (estimated)
- Sponsor
- Beijing Tiantan Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to assess the need for hydrocortisone replacement therapy during the perioperative period for large pituitary neuroendocrine tumors. The main questions it aims to answer are:
• Does hydrocortisone replacement therapy reduce the incidence of adrenal insufficiency in participants? Researchers will compare hydrocortisone to a placebo (a look-alike substance that co…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* (1) Age range: 18-70 years old;
* (2) Accept PitNETs patients who can be treated with endoscopic transsphenoidal surgery;
* (3) The maximum diameter of the tumor is ≥ 2 centimeters;
* (4) Preoperative hypothalamic pituitary adrenal axis integrity;
* (5) The subject or their le…
Contacts